Blueshift Asset Management LLC Buys Shares of 12,457 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Blueshift Asset Management LLC bought a new stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 12,457 shares of the biotechnology company’s stock, valued at approximately $552,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RCKT. Lazard Asset Management LLC boosted its position in Rocket Pharmaceuticals by 2,708.0% during the 2nd quarter. Lazard Asset Management LLC now owns 1,404 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 1,354 shares in the last quarter. First Mercantile Trust Co. boosted its position in shares of Rocket Pharmaceuticals by 28.4% in the 1st quarter. First Mercantile Trust Co. now owns 2,112 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 467 shares in the last quarter. E Fund Management Co. Ltd. acquired a new stake in shares of Rocket Pharmaceuticals in the 1st quarter worth $115,000. Quantbot Technologies LP boosted its position in shares of Rocket Pharmaceuticals by 308.6% in the 1st quarter. Quantbot Technologies LP now owns 2,860 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 2,160 shares in the last quarter. Finally, Amundi Asset Management US Inc. acquired a new stake in shares of Rocket Pharmaceuticals in the 1st quarter worth $231,000. 96.80% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have recently weighed in on RCKT. Chardan Capital reissued a “buy” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, September 7th. William Blair reissued a “buy” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 10th. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 10th. Finally, SVB Leerink reaffirmed a “buy” rating on shares of Rocket Pharmaceuticals in a research report on Sunday, September 19th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $69.38.

NASDAQ RCKT opened at $28.03 on Thursday. The stock has a 50-day simple moving average of $32.00 and a two-hundred day simple moving average of $39.36. The firm has a market capitalization of $1.81 billion, a P/E ratio of -9.98 and a beta of 1.72. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $26.72 and a fifty-two week high of $67.48. The company has a debt-to-equity ratio of 0.04, a quick ratio of 16.92 and a current ratio of 16.92.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings data on Monday, August 9th. The biotechnology company reported ($0.55) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.66) by $0.11. During the same period in the previous year, the business posted ($0.45) EPS. As a group, analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.38 earnings per share for the current year.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms.

Featured Story: Why is the conference call important?

Institutional Ownership by Quarter for Rocket Pharmaceuticals (NASDAQ:RCKT)

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.